Low-dose SKA Progesterone and Interleukin-10 modulate the inflammatory pathway in endometriotic cell lines

Mancini, Francesca; Milardi, Domenico; Carfagna, P; Grande, Giuseppe; Miranda, Vincenzo; Nardone, Alessandra; Ricciardi, Domenico; Pontecorvi, Alfredo; Marana, Riccardo; Nardone, Fiorenzo De Cicco

doi:10.1016/j.intimp.2017.12.008

Cited by 14 publications

(12 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results revealed the potential of LD BMP4 (9.35 × 10 −15 µg/mL) to effectively inhibit PGE2 release in hGF under inflammatory stimulus. Importantly, other MIM containing IL1β (17CH), TNF‐α (17CH) and IL2 (10CH) 19 or Progesterone (10 pg/mL) and IL10 (10 fg/mL) 37 have shown in vitro beneficial anti‐inflammatory effects in other inflammatory related diseases. Moreover, in some recent works, the use of BMP7 as a direct anti‐inflammatory agent resulted in the inhibition of cardiac pathophysiology 6,38 .…”

Section: Discussionmentioning

confidence: 99%

BMP4 micro‐immunotherapy increases collagen deposition and reduces PGE2 release in human gingival fibroblasts and increases tissue viability of engineered 3D gingiva under inflammatory conditions

Ferrà-Cañellas

Munar-Bestard

Garcia-Sureda³

et al. 2021

Journal of Periodontology

View full text Add to dashboard Cite

Background: We aimed to evaluate the effect of low doses (LD) bone morphogenetic protein-2 (BMP2) and BMP4 micro-immunotherapy (MI) in two in vitro models of periodontal wound healing/regeneration. Methods: We first evaluated the effect of LD of BMP2 and BMP4 MI on a 2D cell culture using human gingival fibroblasts (hGF) under inflammatory conditions induced by IL1β. Biocompatibility, inflammatory response (Prostaglandin E2 (PGE2) release), collagen deposition and release of extracellular matrix (ECM) organization-related enzymes (matrix metalloproteinase-1 (MMP1) and metalloproteinase inhibitor 1 (TIMP1)) were evaluated after short (3 days) and long-term (24 days) treatment with BMP2 or BMP4 MI. Then, given the results obtained in the 2D cell culture, LD BMP4 MI treatment was evaluated in a 3D cell culture model of human tissue equivalent of gingiva (GTE) under the same inflammatory stimulus, evaluating the biocompatibility, inflammatory response and effect on MMP1 and TIMP1 release. Results: LD BMP4 was able to decrease the release of the inflammatory mediator PGE2 and completely re-establish the impaired collagen metabolism induced by IL1β treatment. In the 3D model, LD BMP4 treatment improved tissue viability compared with the vehicle, with similar levels to 3D tissues without inflammation. No significant effects were observed on PGE2 levels nor MMP1/TIMP1 ratio after LD BMP4 treatment, although a tendency to decrease PGE2 levels was observed after 3 days. Conclusions: LD BMP4 MI treatment shows anti-inflammatory and regenerative properties on hGF, and improved viability of 3D gingiva under inflammatory conditions. LD BMP4 MI treatment could be used on primary prevention or maintenance care of periodontitis. K E Y W O R D Sbone morphogenetic protein 4, gingiva, in vitro technique, periodontitis, bone morphogenetic protein 2

show abstract

Section: Discussionmentioning

confidence: 99%

BMP4 micro‐immunotherapy increases collagen deposition and reduces PGE2 release in human gingival fibroblasts and increases tissue viability of engineered 3D gingiva under inflammatory conditions

Ferrà-Cañellas

Munar-Bestard

Garcia-Sureda³

et al. 2021

Journal of Periodontology

View full text Add to dashboard Cite

show abstract

“…Eight of the remaining 36 studies were excluded, 10 11 12 13 14 15 16 17 leaving 17 publications related to GUNA products, 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 eight to LABO'LIFE products, 35 36 37 38 39 40 41 42 two to Boiron products 43 44 and one to a product manufactured by Laboratorios Medicor 45 as the principal basis for this scoping review.…”

Section: Resultsmentioning

confidence: 99%

The Clinical and Biological Effects of Homeopathically Prepared Signaling Molecules: A Scoping Review

Manchanda¹,

Gupta²,

Gupta³

et al. 2021

Homeopathy

View full text Add to dashboard Cite

Background Signaling molecules such as cytokines and interleukins are key mediators for the immune response in responding to internal or external stimuli. Homeopathically prepared signaling molecules have been used therapeutically for about five decades. However, these types of products are not available in many countries and their usage by homoeopaths is also infrequent. The aim of this scoping review is to map the available pre-clinical and clinical data related to the therapeutic use of homeopathically prepared signaling molecules. Methods We conducted a scoping review of clinical and pre-clinical studies of therapeutically used signaling molecules that have been prepared in accordance with an officially recognized homeopathic pharmacopoeia. Articles in peer-reviewed journals reporting original clinical or pre-clinical research of homeopathically prepared signaling molecules such as interleukins, cytokines, antibodies, growth factors, neuropeptides and hormones, were eligible. Non-English language papers were excluded, unless we were able to obtain an English translation. An appraisal of eligible studies took place by rating the direction of the outcomes on a five-point scale. The quality of the papers was not systematically assessed. Results Twenty-eight eligible papers, reporting findings for four different manufacturers' products, were identified and reviewed. Seventeen papers reported pre-clinical studies, and 11 reported clinical studies (six experimental, five observational). A wide range of signaling molecules, as well as normal T-cell expressed specific nucleic acids, were used. A majority of the products (21 of 28) contained two or more signaling molecules. The most common clinical indications were psoriasis, vitiligo, rheumatoid arthritis, respiratory allergies, polycystic ovary syndrome, and herpes. The direction of the outcomes was positive in 26 papers and unclear in two papers. Conclusion This scoping review found that there is a body of evidence on the use of homeopathically prepared signaling molecules. From a homeopathy perspective, these substances appear to have therapeutic potential. Further steps to explore this potential are warranted.

show abstract

“…During the last years, several in vivo/in vitro studies and clinical trials have reported the effectiveness and safety of the therapeutic intervention based on the oral administration of LD of signaling molecules in different pathological conditions, including inflammation and oxidative stress 49,50. The proposed action mechanism of LD cytokines, hormones, neuropeptides, and growth factors involves the activation of cellular and plasmatic receptors by virtue of their LD.…”

Section: Discussionmentioning

confidence: 99%

<p>Effect of the micro-immunotherapy medicine 2LPARK® on rat primary dopaminergic neurons after 6-OHDA injury: oxidative stress and survival evaluation in an in vitro model of Parkinson’s disease</p>

Lilli¹,

Révy²,

Robelet³

et al. 2019

DNND

View full text Add to dashboard Cite

Background Parkinson’s disease (PD) is a neurodegenerative disease characterized by motor impairments and resulting from progressive degenerative loss of midbrain dopaminergic (DAergic) neurons in the substantia nigra. Although the main cause of the loss of DAergic neurons is still unknown, various etiopathogenic mechanisms are distinguished, including release and accumulation of endogenous excitotoxic mediators along with the production of oxidative free radicals. Several neurotrophic and growth factors are known to increase DAergic neuronal survival and enhance antioxidant mechanisms. In this context, the micro-immunotherapy (MI) approach consists to regulate the immune system in order to protect DAergic neurons and control oxidative stress. Purpose The aim of the present study was to investigate the effect of the MI medicine (MIM), 2LPARK ® (Labo’Life), on oxidative stress and on the number of neurons positive for tyrosine hydroxylase (TH), in an in vitro model of PD. Methods Rat primary mesencephalic DAergic neurons cultures were pre-treated for 1 hr with the MIM (10 μM and 10 mM), placebo (10 μM and 10 mM) or brain-derived neurotrophic factor (BDNF; 3.3 μM) and then intoxicated with 6-hydroxydopamine (6-OHDA; 20 μM) for 48 hrs. After incubation, cells were incubated 30 mins at 37°C with CellROX green reagent and number of labeled cells were quantified. Then, cells were fixed and incubated with anti-TH antibody and the number of TH + neurons was evaluated. Results We showed that, contrary to placebo, MIM was able to reduce oxidative stress and protect DAergic neurons from 6-OHDA-induced cell death. Conclusion Our results demonstrate the in vitro efficacy of MIM on two essential mechanisms of PD and propose the MI approach as a new ally in the regulation of neuroinflammation and in the treatment of this degenerative disease.

show abstract

Low-dose SKA Progesterone and Interleukin-10 modulate the inflammatory pathway in endometriotic cell lines

Cited by 14 publications

References 45 publications

BMP4 micro‐immunotherapy increases collagen deposition and reduces PGE2 release in human gingival fibroblasts and increases tissue viability of engineered 3D gingiva under inflammatory conditions

BMP4 micro‐immunotherapy increases collagen deposition and reduces PGE2 release in human gingival fibroblasts and increases tissue viability of engineered 3D gingiva under inflammatory conditions

The Clinical and Biological Effects of Homeopathically Prepared Signaling Molecules: A Scoping Review

<p>Effect of the micro-immunotherapy medicine 2LPARK® on rat primary dopaminergic neurons after 6-OHDA injury: oxidative stress and survival evaluation in an in vitro model of Parkinson’s disease</p>

Contact Info

Product

Resources

About